Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib in relapsed or metastatic poorly differentiated or undifferentiated thyroid carcinoma
ChiCTR2000033701Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid cancer (ATC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate. Started Jun 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
poorly differentiated thyroid carcinoma (PDTC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on ChiCTR2000033701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033701.